U.S. House · 117th Congress · H.R. 6832
H.R. 6832
To amend the Federal Food, Drug, and Cosmetic Act and the Defense Production Act of 1950 to prohibit the Federal Government from limiting State access to key therapies, such as monoclonal antibodies, and from prioritizing Federal contracts over State contracts relating to purchasing supplies to combat the COVID-19 pandemic.
Follow
Log in to follow this bill and get an email when there’s a new vote (premium).
- Sponsor
- Michael CloudR-TX-27
- Introduced
- February 25, 2022, in the House
- Issue areas
- Policy area
- Health (from the Congressional Research Service)
- Full text and actions
- congress.gov
Votes on this bill (0)
Neither the House nor the Senate has held a roll-call vote on this bill.
Cosponsors (6)
6 Republicans. Each member is shown with the party they were counted with on the day they signed on. How we count these
Original cosponsors
- Andy BiggsR-AZ-5
- Byron DonaldsR-FL-19
- Mary E. MillerR-IL-15
- Thomas P. TiffanyR-WI-7
- Daniel WebsterR-FL-11
Signed on later
- Mo BrooksR-AL-5February 28, 2022